Uppsala, Sweden – While attending CICON23, scientists from Strike Pharma presented two scientific posters demonstrating progress in the preclinical development of STRIKE2001-KRAS and in the use of the ADAC^TM technology platform for drug cargo delivery:

‘STRIKE2001-KRAS, a novel CD40-targeting agonistic antibody carrying KRAS peptide cargo via a modular drug cargo loading principle (ADAC) leading to simultaneous agonism and antigen-presentation in vivo’ can be downloaded here

‘The Adaptable Affinity Drug Conjugate (ADAC) targeting CD40 facilitates modular neoantigen peptide delivery through affinity-based drug cargo delivery’ can be downloaded here

ENDS

About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as cancer immunotherapeutic treatments. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.

Enquiries

Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]